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γδ T cells are not MHC restricted, elicit cytotoxicity against various malignancies, are
present in early post-transplant phases in novel stem cell transplantation strategies and
have been shown to mediate antibody-dependent cellular cytotoxicity (ADCC) with mon-
oclonal antibodies (mAbs). These features make γδ T cells promising effector cells for
antibody-based immunotherapy in pediatric patients with B-lineage acute lymphoblastic
leukemia (ALL). To evaluate combination of human γδ T cells with CD19 antibodies for
immunotherapy of B-lineage ALL, γδ T cells were expanded after a GMP-compliant pro-
tocol and ADCC of both primary and expanded γδ T cells with an Fc-optimized CD19
antibody (4G7SDIE) and a bi-specific antibody with the specificities CD19 and CD16 (N19-
C16) was evaluated in CD107a-degranulation assays and intracellular cytokine staining.
CD107a, TNFα, and IFNγ expression of primary γδT cells were significantly increased and
correlated with CD16-expression of γδ T cells. γδ T cells highly expressed CD107a after
expansion and no further increased expression by 4G7SDIE and N19-C16 was measured.
Cytotoxicity of purified expanded γδT cells targeting CD19-expressing cells was assessed
in both europium-TDA release and in an impedance-based label-free method (using the
xCELLigence system) measuring γδ T cell lysis in real-time. Albeit in the 2 h end-point
europium-TDA release assay no increased lysis was observed, in real-time xCELLigence
assays both significant antibody-independent cytotoxicity and ADCC of γδ T cells were
observed. The xCELLigence system outperformed the end-point europium-TDA release
assay in sensitivity and allows drawing of conclusions to lysis kinetics of γδ T cells over
prolonged periods of time periods. Combination of CD19 antibodies with primary as well
as expanded γδT cells exhibits a promising approach, which may enhance clinical outcome
of patients with pediatric B-lineage ALL and requires clinical evaluation.
Keywords: γδT cell expansion, ADCC, tumor immunotherapy, therapeutic antibodies, xCELLigence system
INTRODUCTION
Pediatric B-lineage acute lymphoblastic leukemia (ALL) is the
most common childhood malignancy and the leading cause
of cancer-related death during childhood (1). Improvement of
chemotherapeutic protocols as well as application of allogeneic
stem cell transplantation (SCT) in relapsed or refractory patients
has improved outcome tremendously. Graft manipulation strate-
gies have evolved from CD34-positive selection over CD3/CD19
depletion to TCRαβ/CD19 depletion, leaving γδ T cells in the
graft and which is currently applied in phase I/II clinical stud-
ies (2–4). In contrast to αβ T cells, γδ T cells are not restricted
by MHC molecules, which makes them unlikely to elicit graft ver-
sus host disease (GvHD) based on HLA alloreactivity (5). This
feature makes γδ T cells potent effector cells not only during
early lymphopenic post-transplant phase but also in cell-based
immunotherapy after SCT.
Immunotherapy with CD20-specific monoclonal antibodies
(mAbs) Rituximab and Ofatumumab has shown promising clin-
ical results in B-cell malignancies. However, CD20 is expressed
in <50% of pediatric B-lineage ALLs, thus, limiting the potential
use of CD20 antibodies to a minor patient cohort (6, 7). CD19,
another signature B-cell antigen, is expressed from early B-cell
development onward and, thus, expressed on all B-lineage ALLs
making it a well suited target antigen (8, 9). Several CD19 antibod-
ies are currently in pre-clinical and early clinical evaluation (7–12).
Main effector function of these mAbs is antibody-dependent cel-
lular cytotoxicity (ADCC), which is mediated by the activating
low-affinity receptor FcγRIIIa (type III receptor for IgG; CD16),
which binds the Fc portion of human antibodies of the subclasses
IgG1 and IgG3. Engagement of CD16 induces a potent activat-
ing signal, which overcomes inhibitory signals and results in one
or more of the effector functions ADCC, cytokine response, and
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phagocytosis (13). ADCC is mediated by the release of cytotoxic
granules containing perforin and granzyme leading to the lysis of
target cells. The relevance of ADCC in vivo has been underlined
by a recent study showing improved clinical response in patients
showing higher capacity for ADCC in vitro (14). CD16 is highly
expressed by natural killer (NK) cells and by other hematopoietic
cells including macrophages and granulocytes.
γδT cells share several surface antigens with NK cells, including
NKG2D, ULBP, CD56, and CD16 (15). CD16-expression of circu-
lating Vγ9Vδ2 T lymphocytes may be induced by activating γδ T
cells with phosphoantigens and this distinct subset of effector cells
has been shown to be highly cytolytic against tumor cells upon
activation via CD16 (16, 17). ADCC induced by CD16-expressing
γδ T cells has been shown for therapeutic antibodies as Rituximab
and Trastuzumab (18, 19).
Besides second generation mAbs as chimerized antibody Rit-
uximab and humanized antibody Trastuzumab, several third-
generation antibodies have been developed in order to further
enhance ADCC in vivo and, thus, improving clinical efficacy
(20). The main approaches to optimize FcγRIIIa binding by
enhancing the affinity of mAbs developed in recent years, were
molecular modifications in the Fc domain of mAbs leading to
amino acid substitutions (21–23), modifying Fc-linked glycosy-
lation (24–26) and replacement of the reactive Fc portion by a
binding domain for CD16 (27). For treatment of acute myeloid
leukemia (AML) several of these third-generation constructs are
currently under pre-clinical and early clinical investigation and
have been shown to mediate higher ADCC than their unmodified
counterparts (28–30).
The standard techniques to determine the antibody-
independent cytotoxicity (AIC) and ADCC in vitro include
51chromium release assays, Europium-TDA assays, [(3)H]
thymidine incorporation assays, MTT assays, and flow cytometry-
based CD107a-degranulation assays (31–35). However, those
methods share various limitations including the labeling of cells
and that they can only be readily performed as end-point assays,
thereby lacking the information required for kinetic studies (36).
Recent studies reported on the deployment of a novel label-free
electrical impedance-based assay allowing the dynamic detec-
tion of AIC and ADCC and suggest several advantages com-
pared to other established killing assays. This technique, based
on the continuous assessment of electrical impedance, has been
validated for the assessment of NK cell AIC and ADCC and
antigen-specific T-cell-mediated cytotoxicity and deployed for the
assessment of γδT cell-mediated cytotoxicity with bi-specific anti-
bodies binding CD3 and Vγ9 on γδ T cells, respectively (36–38).
Impedance to an electric current is increased by the isolating
properties of the cell body, when adherent tumor cells attach to
electrodes on the bottom of multi-well plates. Killing of these
tumor cells results in detachment or disintegration, reducing the
electrical impedance that can be measured by the xCELLigence
system (36).
Here, we not only show that primary as well as expanded
γδ T cells mediate ADCC with an Fc-optimized CD19 antibody
and a CD19–CD16 bi-specific construct but present a label-free
impedance-based method, facilitating the detection of γδ T cell
lysis kinetics over prolonged periods of time.
MATERIAL AND METHODS
CELLS AND CULTURE CONDITIONS
PBMC from leukocytes of thrombapheresises of healthy blood
donors and leukemic blasts were isolated by density gradient cen-
trifugation using Biocoll Separating Solution (Biochrom, Berlin,
Germany). Healthy donor samples were kindly provided by the
Institute for Clinical and Experimental Transfusion Medicine
at Tübingen University after obtaining written informed con-
sent. Primary leukemic blasts were obtained from a patient with
common-ALL. Over 90% of bone marrow cells were positive
for CD10/CD34/CD19 as determined by flow cytometry. PBMC,
leukemic blasts, and pediatric B-lineage ALL cell line SEM (ACC
546, DSMZ, Braunschweig, Germany) were cultured in IMDM
(Lonza, Basel, Switzerland), breast adenocarcinoma cell line MCF-
7 (ACC 115), and B-lineage ALL cell line NALM-6 (ACC 128)
were kept in EMEM and RPMI 1640 (Biochrom), respectively. All
media were supplemented with 10% fetal calf serum or pooled
human AB serum (Invitrogen, Karlsruhe, Germany), 100 U/ml
penicillin, 100µg/ml streptomycin, 1 mM sodium pyruvate, and
2 mM L-glutamine (all reagents Biochrom).
MCF-7 TRANSFECTANT
Full-length cDNA of human CD19 (GenBank no. BC006338.2)
was purchased from source Bioscience (Berlin, Germany) and
cloned into the expression vector pGH-1. MCF-7 cells were trans-
fected by electroporation (230 V, 975µF) and CD19 expressing
clones were selected and sorted by flow cytometric analysis.
Stable CD19 expression of transfected MCF-7 (termed MCF-
7-CD19tm) was verified over course of culture. Medium of
selected clones was supplemented with 1 mg/ml G418-BC sulfate
(Biochrom).
ANTIBODIES AND FLOW CYTOMETRY
Initial chimerization and Fc-optimization of χ4G7 and 4G7SDIE,
respectively, was described previously (28). For a good manu-
facturing practice (GMP)-compliant production, antibody genes,
codon-usage optimized for CHO expression, were inserted into
the expression vector pGH-1 and used for serum-free transfec-
tion of CHO cells. The antibody 4G7SDIE was then produced
by transfected CHO cells and purified in GMP-compliant clean
rooms using disposable technology including a 100-l biowave
reactor (Sartorius, Goettingen, Germany) for fermentation and
an ÄKTA ready system for purification by protein A, ion exchange,
and hydrophobic interaction chromatography (MabSelect SuRe
and Capto-Adhere columns, GE Healthcare, Munich, Germany).
N19-C16 (CD19–CD16) and N19-CU (CD19–CD3) were gener-
ated in a bi-specific format, termed Fabsc. This bi-specific format
contains the CD19 antibody (clone 4G7) as a Fab fragment, which
is linked by an Fc-attenuated CH2 domain to a C-terminal single-
chain Fv fragments derived from the CD16 antibody (clone 3G8)
and the CD3 antibody (clone UCHT1), respectively (Durben et al.,
manuscript submitted). The constructs were produced by trans-
fected Sp2/0 cells and purified by affinity chromatography with
κ-select (GE Healthcare).
CD107a-APC, CD56-PE/Cy7, CD45-APC/Cy7, CD3-PerCP,
IFNγ-BV711, TNFα-PB, CD16-AF700, CD4-BV421, CD8-
APC/Cy7, and isotype control antibodies were purchased from
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Biolegend (San Diego, CA, USA). TCRγδ-FITC, CD19-PE, CD56-
PE, and anti-human CD19 antibody (clone 4G7) were purchased
from BD Biosciences (Heidelberg, Germany) and LIVE/DEAD
Fixable Aqua and Yellow Dead Stain Kits from Invitrogen. All anti-
bodies were incubated with cells for 20 min at 4°C. Quantitative
analysis was performed with QIFIKIT (Dako, Hamburg, Ger-
many) according to the manufacturers’ recommendations. Cells
were analyzed with a FACSCalibur or a LSRII and sorted with a
FACSJazz (BD Biosciences).
CD107a-DEGRANULATION ASSAY
Percentage of γδ T cells (CD3+, TCRγδ+) was determined by flow
cytometry and donors with γδ T cells >1.5% were selected for
CD107a assays. Equal cell numbers of PBMC and NALM-6 or
SEM were incubated with 1µg/ml 4G7SDIE or N19-C16, 2µM
GolgiStop (BD Biosciences), 10µg/ml Brefeldin A (Sigma, Stein-
heim, Germany) and CD107a-APC overnight at 37°C, 5% CO2
in supplemented IMDM. Subsequently, PBMC were stained for
surface and intracellular markers and analyzed by flow cytometry.
EXPANSION OF γδ T CELLS
PBMC were seeded at 1.5× 106 per well in 24-well plates and
cultured in supplemented IMDM containing 100 IU/ml of recom-
binant human IL-2 (rhIL-2) (Novartis, Basel, Switzerland) and
400 nM zoledronate (Hexal, Holzkirchen, Germany). Every 2–
3 days medium containing 100 IU/ml rhIL-2 and 400 nM zole-
dronate was added. After 12–14 days of culture expanded pop-
ulations were positively selected using a Hapten-modified anti
TCR-γδ antibody and FITC-conjugated anti-Hapten MicroBeads
with the autoMACS system (Miltenyi Biotec, Bergisch Gladbach,
Germany). Purity of the isolated populations was determined by
flow cytometric analysis and isolated cells were incubated with
400 IU/ml rhIL-2 overnight prior to functional assays. After 24 h
isolated γδT cells had lost their FITC-labeling and restored TCRγδ
surface expression (data not shown).
REAL-TIME CYTOTOXICITY ASSAY (xCELLIGENCE ASSAY)
The cytolytic potential of expanded and isolated γδ T cells was
analyzed in a real-time cytotoxicty assay with an xCELLigence
RTCA SP instrument (ACEA Biosciences, San Diego, CA, USA).
In each well 5× 103 MCF-7-CD19tm cells were seeded. After 20–
24 h expanded γδT cells and 1µg/ml 4G7SDIE and N19-C16 were
added, respectively. Cell viability was monitored every 15 min for
48 h. Cell indexes (CIs) were normalized to CI of the time-point
when γδ T cells were added and specific lysis was calculated in
relation to the control cells lacking any effector γδ T cells.
EUROPIUM-TDA CYTOTOXICITY ASSAY
The cytolytic activity of expanded and isolated γδ T cells was ana-
lyzed in a 2 h-DELFIA EuTDA cytotoxicity assay (PerkinElmer,
Waltham, MA, USA) according to the manufacturers recommen-
dations and as described previously (39). Briefly, cryopreserved
primary B-lineage ALL blasts were labeled with the fluorescence
enhancing ligand BATDA for 60 min at 37°C. After five wash
cycles 5× 103 target cells per well were seeded and γδ T cells and
1µg/ml 4G7SDIE and N19-C16 were added, respectively. After co-
culture of 2 h, 20µl of supernatant was mixed with 200µl DELFIA
Europium Solution and after 15 min fluorescence of Europium-
TDA chelates was quantified using a VICTOR multi label reader
(Wallac, Turku, Finland). Specific lysis was calculated as fol-
lows: % specific lysis= (experimental TDA release− spontaneous
TDA release)/(maximum TDA release− spontaneous TDA
release)× 100.
GRAPHICAL AND STATISTICAL ANALYSIS
Flow cytometry data were analyzed with FlowJo software (Tree
Star, Ashland, OR, USA) and xCELLigence data were analyzed
with RTCA Software 1.2 (ACEA Biosciences). Other analyses were
performed using GraphPad Prism software (GraphPad Software,
La Jolla, CA, USA). Statistical significance was accepted at p< 0.05
and is indicated by *(p< 0.05), **(p< 0.01), ***(p< 0.001), and
****(p< 0.0001).
RESULTS
EXPANSION OF HUMAN CD16+ γδ T CELLS
Human γδ T cells, obtained from leukapheresis products from
six healthy volunteers, were expanded after a GMP-compliant
protocol using 400 nM zoledronate and 100 IU/ml rhIL-2. After
12–14 days of culture γδ T cells were enriched from 2.87%± 1.48
of PBMC prior to expansion to 42.35%± 10.85 of cultured cells.
A 1.27-fold ±0.49 expansion of total cells and a 22.55-fold ±9.91
expansion of γδ T cells were observed. Percentage of CD16+
γδ T cells reached 26.55%± 6.02 after expansion (Table 1). As
described previously, expanded γδ T cells exhibited an continuum
of CD16-expression (data not shown) (17, 18).
INDIRECT DETECTION OF CYTOTOXICITY OF PRIMARY γδ T CELLS AND
CD19-SPECIFIC ANTIBODY CONSTRUCTS AGAINST CD19+ LEUKEMIC
CELL LINES
Due to low percentages of primary γδ T cells in PBMC samples
(Table 1), isolation of sufficient numbers of γδ T cells in order to
perform cytotoxicity assays may be challenging. Hence, an assay
detecting the activation of γδ T cells in PBMC samples deploy-
ing the degranulation marker CD107a as well as simultaneously
measuring cytokine production by intracellular cytokine stain-
ing (ICS) for IFNγ and TNFα was established. PBMC samples
were incubated with pediatric B-cell precursor leukemia cell lines
NALM-6 or SEM and CD19 antibody 4G7SDIE or N19-C16 con-
structs. CD107a, IFNγ, and TNFα expression of CD3+TCRγδ+ γδ
T cells were determined using flow cytometry. γδ T cells incubated
with NALM-6 or SEM and γδ T cells incubated with irrelevant
control antibody and NALM-6 or SEM, respectively, displayed
low expression of CD107a, IFNγ, and TNFα (Figure 1). How-
ever, Fc-optimized CD19 antibody 4G7SDIE enhanced CD107a
and TNFα expression of γδ T cells, when incubated with target cell
lines, significantly (Figure 1A). IFNγ expression was significantly
enhanced as well, though percentages of positive cells remained
low. Without adding target cell lines, γδ T cells incubated with
4G7SDIE did not express significantly enhanced levels of CD107a,
IFNγ, and TNFα (Figure 1A). The chimerized, unmodified coun-
terpart of 4G7SDIE, χ4G7, did not increase CD107a, IFNγ, and
TNFα expression of γδT cells when incubated with target cell lines
NALM-6 (Figure 1B). Bi-specific CD19–CD16 antibody construct
N19-C16 induced a significantly enhanced CD107a, IFNγ as well
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Table 1 | Expansion of human γδT cells.
Donor γδT cells prior to
expansion (%)
Days of
expansion
γδT cells after
expansion (%)
CD16+ γδT cells
after expansion (%)
Fold-expansion
of total cells
Fold-expansion
of γδT cells cells
1 2.24 13 35.9 22.70 0.93 14.84
2 1.60 13 43.8 30.26 1.12 30.66
3 4.51 14 60.6 35.10 2.13 28.59
4 1.20 13 33.8 28.90 0.88 24.84
5 5.18 13 32.0 24.00 1.01 6.22
6 2.50 12 48.0 18.32 1.57 30.13
Mean (SD) 2.87 (±1.61) 13 (±0.63) 42.35 (±10.85) 26.55 (±6.02) 1.27 (±0.49) 22.55 (±9.91)
as TNFα expression of γδ T cells, when incubated with target cell
lines, as well (Figure 1C).
INDIRECT DETECTION OF CYTOTOXICITY OF EXPANDED γδ T CELLS
AND CD19-SPECIFIC ANTIBODY CONSTRUCTS AGAINST CD19+
LEUKEMIC CELL LINES
γδ T cells were expanded as described and the TCRγδ+-cell pop-
ulation was isolated. After cell recovery of 24 h, TCRγδ expression
was restored and CD107a assays, in order to determine AIC and
ADCC, were performed. When analyzing expanded γδ T cells
in CD107a-degranulation assays a high baseline-expression of
CD107a of 30–50% was observed (Figure 1D). Addition of CD19-
specific constructs did not enhance expression of CD107a. TNFα
expression of γδ T cells was marginally enhanced by N19-C16
and 4G7SDIE when incubated with target cell line NALM-6. IFNγ
expression was slightly enhanced by N19-C16 when incubated
with target cell line NALM-6.
CORRELATION OF CD16-EXPRESSION BY PRIMARY γδ T CELLS WITH
ADCC BY CD19-SPECIFIC ANTIBODY CONSTRUCTS
CD16-expression of γδ T cells was not detected simultaneously in
CD107a-degranulation assays due to technical limitations, which
prohibited staining of CD16 when analyzing the CD19-specific
antibody constructs. Hence, PBMC samples were stained for
γδ T cell markers CD3 and TCRγδ as well as CD16 prior to
CD107a-degranulation assays with 4G7SDIE and N19-C16 and
cell line NALM-6 as described above (Figure 2A). Mean percent-
age of CD16-positive γδ T cells was 38.93%± 20.43. Expres-
sion of CD107a, TNFα, and IFNγ induced by target cell line
only was deducted from expression levels reached by incubation
with NALM-6 and CD19-specific antibody constructs. A positive
correlation between CD107a-, TNFα-, and IFNγ-expression by
4G7SDIE (Figure 2B) or N19-C16 (Figure 2C) stimulated γδ T
cells and CD16-positive γδ T cells was observed.
ASSESSMENT OF CYTOTOXICITY OF EXPANDED γδ T CELLS IN
2 H-EUROPIUM-TDA RELEASE ASSAYS
After expansion of γδ T cells the TCRγδ+-cell population was
isolated (purity 99.5%± 0.62) and after cell recovery of 24 h
cytotoxicity assays in order to determine AIC and ADCC were
performed. First, cytotoxicity of isolated, expanded, and recov-
ered γδ T cells was assessed in 2 h-europium-TDA release assays
with pediatric B-lineage ALL blasts. No significant lysis of leukemic
blasts by expanded γδ T cells and γδ T cells with CD19-specific
antibody constructs 4G7SDIE and N19-C16 was observed in this
end-point assay, respectively (Figures 3A,B). As positive control,
2 h-europium-TDA release assays with pediatric B-lineage ALL
blasts, γδ T cells and a CD19–CD3 bi-specific antibody construct
(N19-CU) were performed (Figure 3C). Albeit γδT cells alone did
not lyse pediatric B-lineage ALL blasts, combination of γδ T cells
with N19-CU did greatly enhance lysis.
ASSESSMENT OF CYTOTOXICITY OF EXPANDED γδ T CELLS IN A
LABEL-FREE REAL-TIME ASSAY (XCELLIGENCE)
In order to test the suitability of impedance-based measurement
of cell viability for monitoring γδ T cell-mediated AIC and ADCC
by CD19-specific antibody constructs, CD19-expressing, adher-
ent cells were required. Adherent breast adenocarcinoma cell
line MCF-7 was stably transfected with transmembrane CD19.
A CD19+ clone, expressing CD19 comparable to CD19 surface
expression levels displayed by pediatric B-lineage ALL blasts, was
selected by cell sorting (Figure S1 in Supplementary Material).
MCF-7-CD19 transfected cells of the selected clone (MCF-
7-CD19tm) were seeded on 96-well E-plates and after grow-
ing overnight expanded isolated and recovered γδ T cells were
added in various effector to target ratios (E:T). Medium, con-
trol antibody, CD19-specific antibody constructs 4G7SDIE and
N19-C16 were added at the same time-point, respectively. An
E:T ratio-dependent cytolysis of target cells could be reproducibly
monitored as decreasing impedance values in real-time, whereas
medium controls were not affected in their growing displayed by
continuously increasing normalized CI values (Figures 4A,B).
Depending on E:T ratios, normalized CI values of MCF-7-
CD19tm incubated with expanded γδ T cells reached baseline,
displaying a target cell lysis of 100%, after 24–48 h (Figures 4A,B).
Addition of CD19-specific antibody constructs 4G7SDIE and
N19-C16 greatly enhanced the reduction of normalized CIs of
MCF-7-CD19tm cells. Specific lysis of target cells was calculated
for different time-points (Figures 5A,B). At E:T 20:1 specific
lysis was increasing rapidly over time and reached 79% after 12 h
whereas lysis with E:T 10:1 and E:T 5:1 was increasing less rapidly
over time, reaching 44 and 17% after 12 h, respectively. Addition of
CD19-specific antibody constructs 4G7SDIE and N19-C16 greatly
enhanced the specific lysis of MCF-7-CD19tm cells. Depending on
the time-point to observe AIC and ADCC, differences between γδ
T cells alone (AIC) andγδT cells with CD19-specific antibody con-
structs (ADCC), were more or less pronounced (Figures 5A,B).
Greatest differences of AIC and ADCC were at 4 h (20:1) and 8 h
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FIGURE 1 | Indirect assessment of primary and expanded γδT cell-mediated AIC andADCC in CD107a-degranulation assays and intracellular cytokine
stainings (ICS).
(Continued)
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FIGURE 1 | Continued
PBMC (A–C) or expanded, isolated, and recovered γδT cells (D) were
incubated with equal cell numbers of target cell lines NALM-6 or SEM and
antibodies for 16 h. γδT cell degranulation (CD107a) and cytokine production
(TNFα and IFNγ) were detected on viable, single CD45+CD3+TCRγδ+
lymphocytes by extracellular and intracellular staining and flow cytometric
analysis. (A) PBMC were incubated with or without target cell lines NALM-6
or SEM and 1µg/ml control antibody or 1µg/ml 4G7SDIE. Five different
donors of 5 independent experiments are shown. (B) PBMC were incubated
with target cell line NALM-6 and without antibody, 1µg/ml χ4G7 or 1µg/ml
4G7SDIE. One representative experiment, of three independent experiments
performed, is shown. (C) PBMC were incubated with or without (light gray
bars) target cell lines NALM-6 (black bars) or SEM (gray bars) and without,
1µg/ml control antibody or 1µg/ml N19-C16. Experiments were performed in
triplicates. (D) Expanded, isolated, and recovered γδT cells were incubated
with or without (light gray bars) target cell lines NALM-6 (black bars) or SEM
(gray bars) and without, 1µg/ml N19-C16 or 1µg/ml 4G7SDIE. Experiments
were performed in triplicates. Error bars represent the standard deviation (SD).
(10:1 and 5:1) for 4G7SDIE and 4 h (20:1), 6 h (10:1) and 8 h (5:1)
for N19-C16, respectively.
DISCUSSION
Albeit tremendous improve in outcome of pediatric patients with
B-lineage ALL over the last decades, prognosis for primary refrac-
tory or relapsed patients remains poor. Since immunotherapeutic
therapy with chimeric antigen receptor-modified T cells with
specificity for CD19 have been successful in pediatric patients
with B-lineage ALL, further immunotherapeutic strategies are
emerging (40, 41).
Due to their features including non-MHC restriction, cytotox-
icity against hematological malignancies and capacity for ADCC,
γδ T cells are promising effector cells for immunotherapy of pedi-
atric B-lineage ALL during early post-transplant phase and phase
and cell-based immunotherapy after SCT.
In this study, we evaluated the combination of primary
and expanded human γδ T cells with CD19 antibodies for
immunotherapy of pediatric B-lineage ALL and established an
label-free method, facilitating the long-term and real-time mon-
itoring of γδ T cell-mediated antibody-independent (AIC) and
ADCC.
Indirect cytotoxicity and cytokine production of primary γδ T
cells was analyzed in CD107a-degranulation assays and ICS. A sig-
nificantly increased expression of degranulation marker CD107a
and cytokine production by γδ T cells was observed when tar-
get cells were incubated with PBMC and CD19 antibody con-
structs. However, expanded, isolated, and recovered γδ T cells
were highly CD107a-positive and CD107a expression was not
further enhanced by CD19 antibody constructs. In contrast to Fc-
optimized mAb 4G7SDIE, no activation of γδ T cells was induced
by parental non-optimized antibody χ4G7. This indicates that a
strong activation may be needed for γδ T cell-mediated ADCC.
Measurement of CD107a-degranulation combined with ICS is a
suitable method for analyzing ADCC capacity of untouched, pri-
mary γδT cells without the need to isolate γδT cells. For expanded
γδ T cells direct cytotoxicity assays seem favorable. For Rituximab
it has been shown that γδT cell ADCC is driven by CD16 (42).
We observed a positive correlation between percentages of CD16-
positive γδ T cells and degranulation and cytokine production
upon CD19-specific antibody stimulation. This finding indicates
that CD107a-, TNFα-, and IFNγ-positive γδ T cells belong to the
CD16+ subset of the γδ T cell pool. Inhibiting CD16-mediated
signaling by using a blocking antibody or removing CD16+ γδ T
cells from the γδ T cell population may be possible approaches
to further underline this hypothesis. It has been shown, that the
percentage of CD16+ cells in the γδ T cell pool can be elevated
in response to pro-inflammatory cytokines IL-2, IL-15, and IL-21
(43, 44). Enhancing CD16-expression of γδ T cells in vivo and
in clinical large-scale expansion protocols, respectively, may be
approaches to advance combined immunotherapy with therapeu-
tic antibodies. Examining the effect of these cytokines on γδ T
cell-mediated ADCC would be particularly interesting as it has
been shown that NK cell-mediated ADCC is enhanced by IL-2,
IL-15, and IL-21 as well (7, 45, 46).
CD107a-degranulation assays measure the cytolytic capacity of
effector cells but lack detection of direct cytolysis of target cells.
However, considering the low frequencies of primary γδ T cells,
isolation of sufficient numbers of γδ T cells for direct cytotoxicity
assays may be impracticable. Furthermore, analysis of ADCC of
untouched primary γδ T cells in direct cytotoxicity assays, requir-
ing isolation of cells, is currently challenging as, to our knowledge,
no cell isolation kits are commercially available, which allow iso-
lation of γδ T cells without depleting CD16+ γδ T cells. γδ T
cells were expanded after a protocol, using reagents in pharma-
ceutical quality, making a possible clinical translation achievable.
AIC and ADCC of expanded, isolated and recovered γδ T cells
was analyzed in 2 h-europium-TDA assays. No lysis of leukemic
blasts by expanded γδ T cells alone and with 4G7SDIE and N19-
C16 was measured, respectively. When expanded γδ T cells were
strongly activated by a CD19–CD3-recruiting bi-specific antibody
construct (N19-CU), strongly enhanced lysis was observed. Unlike
CD16, which was expressed by 26.55%± 6.02 of the expanded γδ
T cells, CD3 is expressed by every γδ T cell. Hence, activation of a
significantly greater number of γδT cell can be achieved with anti-
bodies recruiting CD3-positive cells rather than CD16-positive
cells. This end-point assay is feasible for detecting cytotoxicity
of expanded γδ T cells against leukemic blasts. However, potent
and rapid activation of expanded γδ T cells seems to be required.
AIC and ADCC of expanded γδ T cells may be obliterated due
to the short end-point of the assay, which is limited by time-
dependent increase of spontaneous release of TDA by labeled
target cells. Furthermore, no conclusions to lysis kinetics can be
drawn.
Due to the mentioned limitations of the end-point assay, AIC
and ADCC of γδ T cells were detected in real-time cytotoxic-
ity assays (xCELLigence). One drawback of this method is the
requirement of adherent target cells. Since primary leukemic blasts
as well as common leukemic cell lines are suspension cells, a
CD19-expressing target cell line was generated. In consideration
of that the generated cell line MCF-7-CD19tm expressed com-
parable CD19 surface levels to leukemic blasts and commonly
used cell lines, we hypothesize that results obtained in this assay
allow conclusions regarding ADCC by CD19 antibody constructs
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FIGURE 2 | Correlation of CD16-expression by γδT cells and degranulation and cytokine production of antibody-stimulated primary γδT cells.
(Continued)
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FIGURE 2 | Continued
CD16-expression of γδT cells was assessed by flow cytometric analyses prior
to functional assays. Gating hierarchy was: lymphocytes, single cells, viable
cells, CD3+TCRγδ+, TCRγδ+CD16+. Gates were defined based on
marker-negative populations within the viable cells. Three representative
donors are shown. Same gating strategy was used for all samples (A). PBMC
were incubated with equal cell numbers of target cell lines NALM-6 and
antibodies for 16 h. γδT cell degranulation (CD107a) and cytokine production
(TNFα and IFNγ) were detected on viable, single CD3+TCRγδ+ lymphocytes
by extracellular and intracellular staining and flow cytometric analysis.
Expression of CD107a, TNFα, and IFNγ induced by NALM-6 only was
deducted from expression levels reached by incubation with NALM-6 and
4G7SDIE or N19-C16. PBMC were incubated with target cell line NALM-6 and
medium, 1µg/ml 4G7SDIE (B) and 1µg/ml N19-C16 (C), respectively.
Statistical significance was assessed using Pearson’s correlation.
Experiments were performed in triplicates.
FIGURE 3 | Assessment of γδT cell-mediated AIC andADCC in
2h-europium-TDA release assays. Percentage of specific lysis was
detected in europium-TDA release assays after co-incubation of 5000
labeled pediatric B-lineage ALL blasts per well with expanded, isolated and
recovered γδT cells at different E:T ratios (20:1–5:1) and antibodies for 2 h.
The cytolytic activity after 2 h was calculated as the percentage of specific
lysis [= (experimental TDA release− spontaneous TDA release)/(maximum
TDA release− spontaneous TDA release)×100]. Two representative donors
of four are shown. (A) γδT cells (gray line), γδT cells with 1µg/ml control
antibody (light gray line), and γδT cells with 1µg/ml CD19-specific
Fc-optimized mAb 4G7SDIE (black line) were added, respectively. (B) γδT
cells (gray line), γδT cells with 1µg/ml control antibody (light gray line) and
γδT cells with 1µg/ml CD19–CD16-bi-specific antibody construct N19-C16
(black line) were added, respectively. (C) γδT cells (gray line), γδT cells with
100 ng/ml control antibody (light gray line) and γδT cells with 100 ng/ml
CD19–CD3-bi-specific antibody construct N19-CU (black line) were added,
respectively. Experiments were performed in triplicates. Error bars
represent the standard deviation (SD).
and γδ T cells against CD19-expressing leukemic blasts. Signifi-
cant lysis of target cell line MCF-7-CD19tm by expanded γδ T
cells was observed and increased over time. CD19 antibody con-
structs 4G7SDIE and N19-C16 greatly enhanced the specific lysis
of MCF-7-CD19tm cells by expanded γδT cells. Notably, maximal
cytotoxicity of expanded γδ T cells was delayed beyond 24 h and
time-points of reaching maximal cytolysis varied for expanded γδ
T cells alone (AIC) and expanded γδ T cells with CD19 antibody
constructs (ADCC). Depending on the time-point considering
AIC and ADCC, differences between γδ T cells alone (AIC) and
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FIGURE 4 | Dynamic monitoring of expanded γδT cell-mediated AIC and
ADCC (xCELLigence assay). (A,B) MCF-7-CD19tm were seeded into 96-well
E-plates at equal densities of 5000 cells per well. After cell attachment and
expansion, expanded, isolated, and recovered γδT cells at different E:T ratios
(20:1–5:1) and antibodies were added at time-point t 0 (indicated by the
dashed line) Impedance at well bottoms was measured every 15 min for
>48 h and normalized to baseline impedance values with medium only.
Changes in impedance normalized to t 0 are given as dimensionless
normalized cell index (CI). One representative experiment, of four
independent experiments performed, is shown. (A) Medium without effector
cells (black line), γδT cells (green line), γδT cells with 1µg/ml control antibody
(blue line), and γδT cells with 1µg/ml CD19-specific Fc-optimized mAb
4G7SDIE (red line) were added, respectively. (B) Medium without effector
cells (black line), γδT cells (green line), γδT cells with 1µg/ml control antibody
(blue line), and γδT cells with 1µg/ml CD19–CD16-bi-specific antibody
construct N19-C16 (red line) were added, respectively.
γδ T cells with CD19 antibody constructs (ADCC), were more or
less pronounced. These observations underline the importance of
prolonged incubation times in cytotoxicity assays with expanded
γδ T cells and monitoring lysis kinetics by real-time measurement
of AIC and ADCC.
In summary, we show that untouched primary as well as
expanded γδ T cells mediate ADCC with CD19 antibody con-
structs against various targets. Thus, combination of the presented
antibody constructs with primary as well as expanded γδ T cells
exhibit promising immunotherapeutic approaches that require
clinical evaluation. Notably, assays assessing AIC and ADCC of
γδ T cells have some limitations and should be choosen delib-
erately. The assessment of CD107a and cytokine expression is a
feasible method for assessing cytotoxicity of untouched primary
γδ T cells rather than expanded γδ T cells. Europium-TDA release
assays are feasible for expanded γδ T cells but AIC and ADCC of
γδ T cells can be obliterated due to the limited end-point of the
assay and no firm conclusions to lysis kinetics may be drawn. The
xCELLigence system allows to measure lysis kinetics of γδ T cells
over prolonged periods of time and enables the detection of both
AIC and ADCC of expanded γδ T cells against adherent target
cells.
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FIGURE 5 |Time-dependent cytolytic activity of expanded γδT cells in
xCELLigence assays. (A,B) MCF-7-CD19tm were seeded into 96-well
E-plates at equal densities of 5000 cells per well. After cell attachment and
expansion, expanded, isolated, and recovered γδT cells at different E:T ratios
(20:1–5:1) and antibodies were added at time-point t0. Impedance at well
bottoms was measured every 15 min for >12 h and normalized to baseline
impedance values with medium only. The cytolytic activity at different
time-points was calculated as the percentage of specific lysis (= [normalized
CIno effector cells −normalized CIγδT cells (with antibody)]/normalized CIno effector cells ×100).
One representative experiment, of four independent experiments performed,
is shown. (A) γδT cells (gray line), γδT cells with 1µg/ml control antibody
(light gray line) and γδT cells with 1µg/ml CD19-specific Fc-optimized mAb
4G7SDIE (black line) were added, respectively. (B) γδT cells (gray line), γδT
cells with 1µg/ml control antibody (light gray line), and γδT cells with 1µg/ml
CD19–CD16-bi-specific antibody construct N19-C16 (black line) were added,
respectively.
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